

Weekly Meeting with Dr. Hannah



Presenter: Hasan Shaikh
Quantitative Imaging Research and
Artificial Intelligence Lab (QIRAIL)

Oncode Accelerator

What & Why




Dutch public-private consortium to accelerate cancer-therapy R&D. It tackles high cost and long timelines.

Mission





To put real patients at the core of research. Promising treatments reach trials faster with less risk.

Platforms & Therapy Workstreams

1. Platforms


 Patient Cohorts	 Organoids	 Artificial Intelligence
Well-annotated clinical/genomic data for target validation & trial design.	Patient-derived “mini-tumors” for high-fidelity drug screening.	ML tools to predict efficacy, toxicity & ideal patient subgroups.

2. Workstream

 Small Molecules	 Biologics	 Cell & Gene Therapy	 Therapeutic Vaccines
Kinase inhibitors, oral drugs.	Antibodies, ADCs, checkpoint inhibitors.	CAR-T, TIL, gene-edited cells.	Neoantigen & immune-training vaccines.

To make optimal use of our preclinical development infrastructure, we built four preclinical development pipelines, so called Workstreams, representing the development of the four most prominent types of cancer therapies.

Oncode Accelerator Demo Project Timeline



Benefits of Collaboration



Shared Resources

Access data, models, and regulatory expertise.



Lower Risk & Cost

Co-funding reduces financial burden and risk.



Faster Screening

Patient-centric screening accelerates decision-making process.